title: Clinical factors associated with dose escalation of solifenacin for the treatment of overactive bladder in real life practice.
abstract: OBJECTIVE
  To determine the baseline clinical characteristics associated with dose escalation of solifenacin in patients with overactive bladder (OAB).
  
  
  METHODS
  We analyzed the data of patients with OAB (micturition frequency ≥8/day and urgency ≥1/day) who were treated with solifenacin and followed up for 24 weeks. According to our department protocol, all the patients kept voiding diaries, and OAB symptom scores (OABSS) were monitored at baseline and after 4, 12, and 24 weeks of solifenacin treatment.
  
  
  RESULTS
  In total, 68 patients (mean age, 60.8±10.0 years) were recruited. The dose escalation rate by the end of the study was 41.2%, from 23.5% at 4 weeks and 17.6% at 12 weeks. At baseline, the dose escalator group had significantly more OAB wet patients (53.6% vs. 20.0%) and higher total OABSS (10.2±2.4 vs. 7.9±3.5, P=0.032) than the nonescalator group. OAB wet (odds ratio [OR], 4.615; 95% confidence interval [CI], 1.578-13.499; P<0.05) and total OABSS (OR, 1.398; 95% CI, 1.046-1.869; P<0.05) were found to be independently associated with dose escalation.
  
  
  CONCLUSIONS
  Patients who have urgency urinary incontinence and high total OABSS have a tendency for dose escalation of solifenacin.
authors.affiliation: Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
authors.forename: Ji-Youn
authors.initials: JY
authors.lastname: Chun
authors.affiliation: Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
authors.forename: Miho
authors.initials: M
authors.lastname: Song
authors.affiliation: Department of Urology, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan, Korea.
authors.forename: Ji-Yeon
authors.initials: JY
authors.lastname: Han
authors.affiliation: Department of Computer Science and Information Systems, Hanyang Women's University, Seoul, Korea.
authors.forename: Selee
authors.initials: S
authors.lastname: Na
authors.affiliation: Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
authors.forename: Bumsik
authors.initials: B
authors.lastname: Hong
authors.affiliation: Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
authors.forename: Myung-Soo
authors.initials: MS
authors.lastname: Choo
keywords: Muscarinic antagonists; Overactive urinary bladder; Solifenacin
references.citation: Eur Urol. 2008 Sep;54(3):543-62
references.pmid: 18599186
references.citation: Urology. 2001 Jun;57(6):1044-50
references.pmid: 11377301
references.citation: Urology. 2006 Aug;68(2 Suppl):9-16
references.pmid: 16908336
references.citation: Urology. 2013 Nov;82(5):1044-8
references.pmid: 24054438
references.citation: BJU Int. 2011 Feb;107(4):603-11
references.pmid: 20860648
references.citation: BJU Int. 2007 Jun;99 Suppl 3:8-12
references.pmid: 17488367
references.citation: Int Neurourol J. 2011 Sep;15(3):135-42
references.pmid: 22087422
references.citation: BJU Int. 2013 May;111(5):804-10
references.pmid: 23294801
references.citation: Urology. 2009 Jan;73(1):14-8
references.pmid: 18995887
references.citation: Eur Urol. 2005 Sep;48(3):464-70
references.pmid: 15990220
references.citation: Eur Urol. 2009 Jul;56(1):14-20
references.pmid: 19278775
references.citation: BJU Int. 2008 Nov;102(9):1120-7
references.pmid: 18990175
references.citation: Eur Urol. 2005 Sep;48(3):483-7
references.pmid: 16005564
references.citation: Neurourol Urodyn. 2002;21(2):167-78
references.pmid: 11857671
references.citation: BJU Int. 2009 Oct;104(7):960-7
references.pmid: 19388996
references.citation: Lancet Neurol. 2004 Jan;3(1):46-53
references.pmid: 14693111
references.citation: World J Urol. 2011 Apr;29(2):185-90
references.pmid: 19898824